Analysts Offer Predictions for TG Therapeutics Q1 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of TG Therapeutics in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst E. White expects that the biopharmaceutical company will earn $0.28 per share for the quarter. HC Wainwright has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics' Q2 2025 earnings at $0.32 EPS, Q3 2025 earnings at $0.37 EPS and Q4 2025 earnings at $0.42 EPS.

Several other equities analysts also recently weighed in on the stock. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX traded up $0.79 during midday trading on Thursday, hitting $39.23. The company had a trading volume of 4,876,845 shares, compared to its average volume of 2,612,308. TG Therapeutics has a twelve month low of $12.93 and a twelve month high of $40.31. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $6.16 billion, a price-to-earnings ratio of -392.26 and a beta of 2.30. The business has a 50-day simple moving average of $31.07 and a two-hundred day simple moving average of $28.57.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Private Advisor Group LLC increased its stake in TG Therapeutics by 3.9% during the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock worth $337,000 after acquiring an additional 542 shares during the last quarter. New York State Teachers Retirement System acquired a new position in shares of TG Therapeutics in the 3rd quarter valued at about $1,004,000. Amalgamated Bank grew its holdings in shares of TG Therapeutics by 712.0% during the 3rd quarter. Amalgamated Bank now owns 39,528 shares of the biopharmaceutical company's stock worth $925,000 after purchasing an additional 34,660 shares during the period. Principal Financial Group Inc. increased its position in TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after purchasing an additional 725,371 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its holdings in TG Therapeutics by 33.7% in the third quarter. Los Angeles Capital Management LLC now owns 123,401 shares of the biopharmaceutical company's stock valued at $2,886,000 after buying an additional 31,124 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.50% of the stock is currently owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.